About us

SANEMUS AG focuses on investing in company and asset shares in the German healthcare market and offers strategic, financial and merger&acquisition advisory in this context. It was founded in 2006 by experienced healthcare professionals in Munich. The investment focus is exclusively put on the Life Science sector with its submarkets pharmaceutical industry, biotechnology, medical technology, diagnostics and E-health.

Our Mission

We assist to develop commercially attractive companies from promising Start-Ups from the Life Science sector due to the complementary strategic and financial advisory services offered.

We provide strategic input to substantially increase the value of Life Science companies by sophisticated lifecycle und portfolio management as well as strategic partnering.

We advise investors in Life Science investments – either in single investment projects or in Venture Capital or Private Equity Funds – to achieve an individually optimal value increase of their investments.

Current news

German biotechnology start-ups 2020 – status and perspectives

In the article "German Biotechnology Start-ups 2020 - Status and Perspectives" by Dr. Michael Thiel, the status of German biotechnology in 2020 is presented on the one hand, and on the other hand the article aims to provide food for thought…

Dr. Michael Thiel at the expert consultation day Fundraising

On October 22nd, Dr. Michael Thiel will give feedback as an expert at the Fundraising Day of Forum MedTech Pharma e.V. Life Science Start Ups on the optimization of the business plan, P/L, cash flow planning, optimization of the fundraising…

Sonja Terszowski as a reviewer for the business plan competition medical economy

Sonja Terszowski is a reviewer in this year's business plan competition for the medical industry. Here, innovative business ideas from the medical and healthcare industry have the chance to put their medical business concepts in a future-proof…

GNA Biosolutions developing system for rapid Covid-19 testing

The Munich-based company GNA Biosolutions, which was already supported by SANEMUS AG in the Series C financing round in August 2019, has developed a particularly rapid Covid-19 test, which is to be launched on the market in June at the latest. The…